http://www.acc.org/Feed?clinicalTopicID=5f25c4ac-b76f-4970-a93c-15cdf264bed5 Clinical Topic Feed: Dyslipidemia en /Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! 1772469660000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/Cover-Story-The-Adipokine-Hypothesis Fourteen hours a day, nearly every day for a year. That's how long it took Milton Packer, MD, FACC, to write his groundbreaking hypothesis connecting adipokines and visceral adiposity to heart failure with preserved ejection fraction (HFpEF). 1772371140000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/From-the-Member-Sections-Dietary-Guidelines The Dietary Guidelines for Americans (DGA), released every five years by the U.S. Department of Health and Human Services and U.S. Department of Agriculture, are a major driver of U.S. food policy, diet quality and cardiovascular health. 1772370960000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1772370600000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/26/19/59/REVELUTION-More-Coronary-Plaque-Progression-With-Leuprolide-Than-Relugolix-in-Prostate-Cancer In men with localized prostate cancer (PCa) treated with radiation and androgen-deprivation therapy (ADT), treatment with the gonadotropin-releasing hormone (GnRH) leuprolide was associated with a significant 12-month increase in coronary artery plaque volume when compared with treatment with relugolix, according to a brief report of the REVELUTION trial published Feb. 18 in JAMA. 1772199900000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/19/11/58/Management-of-Dyslipidemia-in-People-Living-With-HIV Globally, an estimated 40.8 million people are living with HIV (PWH). Advances in antiretroviral therapy (ART) have enabled PWH to achieve a near-normal life expectancy; however, individuals taking ART remain at approximately twofold higher risk of developing atherosclerotic cardiovascular disease (ASCVD) ... 1771935660000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/17/14/32/Unpacking-CV-Nutritional-Controversies-in-2026 In response to increased controversy over what makes up a healthy diet, a recent JACC: Advances State-of-the-Art Review dives into the evidence both for and against several controversial foods and provides recommendations based on the available literature on cardiovascular health and outcomes. 1771434420000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/17/14/32/No-Direct-Link A meta-analysis of individual patient data on all adverse events in large-scale, long-term trials of statin therapy found increases in hepatic transaminase and other liver function tests related to statin intensity, but found no evidence that statins cause the majority (62 of 66) of other adverse effects listed in statin labeling... 1771434420000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/09/18/56/CORALreef-Lipids Enlicitide decanoate, an oral PCSK9 inhibitor, significantly reduced LDL-C levels in patients with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event, according to results of the CORALreef Lipids trial published Feb. 4 in the NEJM. 1770735000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/04/18/02/The-Case-For-Earlier-LDL-Cholesterol-Lowering Atherosclerosis begins early and progresses silently. Patients requiring secondary prevention have already accumulated decades of low-density lipoprotein cholesterol (LDL-C) exposure resulting in some potentially irreversible arterial aging and injury. 1770232080000 Articles and Stories